Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) rose 51.7% on Thursday . The stock traded as high as C$0.23 and last traded at C$0.22. Approximately 334,187 shares traded hands during mid-day trading, a decline of 36% from the average daily volume of 521,379 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Performance
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The stock has a market capitalization of C$27.69 million, a P/E ratio of -5.54 and a beta of 0.20. The business has a fifty day moving average price of C$0.20 and a 200-day moving average price of C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Insider Trades May Not Tell You What You Think
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Consumer Discretionary Stocks Explained
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
